Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: Results from efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) program

O’Connor, Christopher M.; Miller, Alan B.; Blair, John E.; Konstam, Marvin A.; Wedge, Patricia; Bahit, María Cecilia; Carson, Peter E.; Haass, Markus; Hauptman, Paul J.; Metra, Marco; Oren, Ron M.; Patten, Richard D.; Piña, Ileana L.; Roth, Sherryn; Sackner‐Bernstein, Jonathan; Traver, Brian; Cook, Thomas D.; Gheorghiade, Mihai

doi:10.1016/j.ahj.2010.02.023

Cited by 214 publications

(164 citation statements)

References 22 publications

Supporting

Mentioning

136

Contrasting

Unclassified

Order By: Relevance

“…Among those patients with HF who were hospitalized and were discharged, the overall mortality was 26% during a follow-up of 9.9 months, with 10.7% mortality due to HF 23 . Therefore, the mortality rate of our patients was similar or lower than those in the literature, according to differences in study population, whether outpatient or after hospital discharge, different functional classes, age range and etiologies.…”

Section: Discussionmentioning

confidence: 99%

Dispersão da onda P e índice de volume do átrio esquerdo como preditores na insuficiência cardíaca

Silva¹,

N²,

Torres³

et al. 2013

Arq. Bras. Cardiol.

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Dispersão da onda P e índice de volume do átrio esquerdo como preditores na insuficiência cardíaca

Silva¹,

N²,

Torres³

et al. 2013

Arq. Bras. Cardiol.

View full text Add to dashboard Cite

show abstract

“…Detection of ADHF is primarily accomplished when there is clinical or radiological evidence of congestion such as patient‐reported dyspnea or orthopnea, weight gain, presence of lower extremity edema, visual estimation of jugular venous pressures, or plain film evidence of pulmonary vascular engorgement. Treatment progress with diuresis and discharge planning often revolves around improvement in the clinical signs of congestion and/or symptom improvement; however, these signs remain imperfect surrogates for true intravascular hemodynamics, as shown by ADHF 30‐day readmission rates as high as 25% with a significant proportion (37–48%) attributable to CHF 3, 4, 5, 6…”

Section: Introductionmentioning

confidence: 99%

Bedside Ultrasound Assessment of Jugular Venous Compliance as a Potential Point‐of‐Care Method to Predict Acute Decompensated Heart Failure 30‐Day Readmission

Simon

Schnatz

Romeo

et al. 2018

JAHA

View full text Add to dashboard Cite

BackgroundHeart failure is one of the most costly diagnosis‐related groups, largely because of hospital readmissions. Objective assessment of volume status to ensure optimization before hospital discharge could significantly reduce readmissions. We previously demonstrated an ultrasound method of quantifying percentage of cross‐sectional area (CSA) change of the right internal jugular vein with Valsalva that reliably estimates central venous pressure.Methods and ResultsPatients admitted with acute decompensated heart failure (ADHF) underwent ultrasound measurements of the right internal jugular vein at end‐expiration and during the strain phase of Valsalva to determine a percentage of CSA change. An initial subgroup of patients with right heart catheterization and accompanying ultrasound measurements of the right internal jugular vein identified a percentage of CSA change predictive of right atrial pressure (RAP) ≥12 mm Hg. Images of admitted ADHF patients were obtained at admission and discharge for final analysis. Simultaneous right heart catheterization and right internal jugular vein ultrasound measurements demonstrated that a <66% CSA change predicted RAP ≥12 mm Hg (positive predictive value: 87%; P<0.05, receiver operating characteristic curve). Elevated admission RAP by percentage of CSA change normalized by discharge (P<0.05), indicating that this test is significantly responsive to therapeutic interventions. Using the cutoff value of 66% CSA change, normal RAP at discharge had 91% predictive value for patients avoiding 30‐day readmission (P<0.05).ConclusionsThis bedside ultrasound technique strongly correlates to invasive RAP measurement in ADHF patients, identifies restoration of euvolemia, and is predictive of 30‐day ADHF readmission. This tool could help guide inpatient ADHF treatment and may lead to reduced readmissions.

show abstract

“…After an episode of acute HF, approximately 25 % require readmission within 30 days, 24 and 50 % within 6 months. 25 HF hospitalisations also significantly duce the QoL of patients with HF, most of whom are older adults.…”

Section: Effects On Rehospitalisation and Mortalitymentioning

confidence: 99%

The Role of Ivabradine and Trimetazidine in the New ESC HF Guidelins

Milinković

Rosano

Lopatin

et al. 2016

Cardiac Failure Review

View full text Add to dashboard Cite

TherapeuticsAccess at: www.CFRjournal.com Chronic heart failure (HF), a complex and heterogeneous clinical syndrome, is a major cause of morbidity and mortality worldwide, and represents a major challenge to health care systems. The prevalence of HF and the number of hospitalisations is rising, even more in the ageing population.1 The direct costs of HF management reached 1-2 % of total health care expenditure and approximately two-thirds are attributable to hospitalisations. In 2012, in 197 countries, covering 99 % of the world's population, the overall cost of HF management was estimated at US$108 billion per annum, and is predicted to rise. 4 Around 60 % of total HF patients has HFrEF, which is associated with high reninangiotensin-aldosterone and sympathetic nervous systems activation.Most recent therapeutic improvements in these patients are due to the use of pharmacological agents that modulate these neuro-hormonal axes, angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), beta-blockers and mineralocorticoid receptor antagonists (MRAs). The beneficial effects of these treatments include the reduction of HF mortality by approximately one-third in a period of two decades. Despite this success, HF mortality rates remain high:the 5-year survival is worse than in many cancers. 5,6The 2016 European Society of Cardiology (ESC) HF guidelines recommend ACEI and beta-blockers as first-line therapy in symptomatic patients with HFrEF. 4 However, both registries and clinical reports underline that the treatment of HF patients is suboptimal much more than expected, and that the heart rate is increased despite beta-blocker therapy.7-12 The registry of 12,440 patients demonstrated heterogeneity in treatment strategies, due to the drug side effects and contraindications.7 A European registry 13 reported that only 17 % of patients were receiving the optimal combination and recommended dose of diuretic, ACEI and beta-blockers. Results from a French registry on 50,000 HF patients 14 also confirmed suboptimal treatment of HF, demonstrating that after the first month following hospitalisation for worsening HF, only 47 % received an ACEI, 54 % a beta-blocker, and 17 % MRAs. The I Brazilian Registry of Heart Failure (BREATHE) 15 , conducted in 57 hospitals in Brazil, revealed that 69 % of HF patients were receiving an ACEI or ARB, 60 % a beta-blocker, and 49 % MRAs. However, only 17 % were receiving all three drugs together. Therefore, a need to identify a novel pathways and strategies for HF treatment is obvious and clinically justified. This article reviews the clinical evidence and guidelines recommendations for the use of two novel therapies in HF: ivabradine and trimetazidine. AbstractThe prevalence of heart failure (HF) is increasing, representing a major cause of death and disability, and a growing financial burden on healthcare systems. Despite the use of effective treatments with both drugs and devices, mortality remains high. There is therefore a need for new and effective therapeutic a...

show abstract

Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: Results from efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) program

Cited by 214 publications

References 22 publications

Dispersão da onda P e índice de volume do átrio esquerdo como preditores na insuficiência cardíaca

Dispersão da onda P e índice de volume do átrio esquerdo como preditores na insuficiência cardíaca

Bedside Ultrasound Assessment of Jugular Venous Compliance as a Potential Point‐of‐Care Method to Predict Acute Decompensated Heart Failure 30‐Day Readmission

The Role of Ivabradine and Trimetazidine in the New ESC HF Guidelins

Contact Info

Product

Resources

About